Interferon Regulatory Factor 3 (IRF3) antibody

Antigen: Interferon Regulatory Factor 3 (IRF3)

Synonyms: IRF-3, MGC91046, C920001K05Rik, MGC94729, IRF3, irf3

Clonality: Monoclonal (SL-14-2)

Host: Mouse

Reactivity: Human

Conjugate: Un-conjugated

Application: Western Blotting (WB)

Catalog no.: ABIN967306

Additional Information

Alternative name: IRF-3

Components: 1) 51-6931GR: Purified Mouse Anti-Human IRF3.
Quantity: 50 µg (1 ea).
Concentration: 0.25 mg/ml.
Clone: SL-14.2.
Immunogen: Human IRF-3 recombinant fusion protein.
Isotype: Mouse IgG1.
Molecular Weight: 50-55 kDa.
Storage Buffer: Aqueous buffered solution containing BSA, glycerol, and Less or equal than 0.09% sodium azide.

2) 51-16526N: Jurkat Cell Lysate.
Quantity: 50 µg (1 ea).
Concentration: 1.0 mg/ml.
Storage Buffer: SDS-PAGE buffer (62mM Tris pH 6.8, 2% SDS, 0.9% b-mercaptoethanol, 0.003% bromophenol blue, 5% glycerol).

Format: Liquid

Isotype: IgG1

Clone: SL-14-2

Description: Viral infection in mammals can lead to the induction of multiple pathways as part of the host defense mechanism. One of the major pathways activated is the JAK-STAT pathway by various interferons (IFNalpha and IFNbeta). These IFNs exert their influence via transcriptional activation of specific target genes involved in anti-viral defense, for example the chemokine ISG15 gene or the major histocompatibility complex class I and II molecules. These genes in turn are regulated by the JAK-STAT signaling pathway and through interferon regulatory factors (IRFs). IRFs are a family of transcription factors which possess a broad range of activities. IRF-3 is one of nine members which all share a common DNA binding domain which binds to IFN stimulated response element (ISRE) found in the majority of IFN-inducible promoters. The IRF-3 gene expresses a 50 kDa protein which is constitutively expressed in all tissues. The protein undergoes post-translational modification as well as dimerization and is translocated from the cytoplasm to the nucleus upon viral infection or exposure to dsRNA. The antibody recognizes human IRF-3. A purified recombinant GST-IRF-3 fusion protein corresponding to human IRF-3 was used as the immunogen.

Characteristics: 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
4. Source of all serum proteins is from USDA inspected abattoirs located in the United States.

Comments:

Related Products: ABIN968537, ABIN967389

Application Details

Application Notes: Applications include western blot analysis (1.0-4.0 µg/ml). Store the antibody at -20°C. The antibody will only recognize the cytoplasmic form of IRF-3 and can not block IRF-3 DNA binding, although this application has not been tested. Jurkat control lysate [50 µg (1 µg/µl)] is provided as a western blot positive control (store lysate at -20°C). Additional control lysate (ABIN968537) is sold separately.

Purity: Purified

Purification: Purified from tissue culture supernatant or ascites by affinity chromatography.

Storage: Store undiluted at -20°C.

Restrictions: For Research Use only

Images

Western blot analysis of IRF-3. Lysates from Jurkat cells were probed with anti-human IRF-3 (clone SL-14.2) at concentrations of 4.0 (lane 1), 2.0 (lane 2), and 1.0 myg/ml (lane 3). IRF-3 is identified at ~50-55 kDa.

Publications

Product: Loh, Chang, Fodor et al.: "Dissection of the interferon gamma-MHC class II signal transduction pathway reveals that type I and type II interferon systems share common signalling component(s)." in: The EMBO journal, Vol. 11, Issue 4, pp. 1351-63, 1992 (PubMed).

Reich, Evans, Levy et al.: "Interferon-induced transcription of a gene encoding a 15-kDa protein depends on an upstream enhancer element." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 84, Issue 18, pp. 6394-8, 1987 (PubMed).

Darnell, Kerr, Stark: "Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins." in: Science (New York, N.Y.), Vol. 264, Issue 5164, pp. 1415-21, 1994 (PubMed).

Au, Moore, Lowther et al.: "Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression of interferon-induced genes." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 92, Issue 25, pp. 11657-61, 1996 (PubMed).

Ronco, Karpova, Vidal et al.: "Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity." in: Genes & development, Vol. 12, Issue 13, pp. 2061-72, 1998 (PubMed).

Wathelet, Lin, Parekh et al.: "Virus infection induces the assembly of coordinately activated transcription factors on the IFN-beta enhancer in vivo." in: Molecular cell, Vol. 1, Issue 4, pp. 507-18, 1998 (PubMed).

Hiscott, Pitha, Genin et al.: "Triggering the interferon response: the role of IRF-3 transcription factor." in: Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, Vol. 19, Issue 1, pp. 1-13, 1999 (PubMed).

Mamane, Heylbroeck, Génin et al.: "Interferon regulatory factors: the next generation." in: Gene, Vol. 237, Issue 1, pp. 1-14, 1999 (PubMed).